← Browse by Condition
Medical Condition

egfr

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for egfr sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — egfr Clinical Trials

How many clinical trials are currently recruiting for egfr?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for egfr, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for egfr?
egfr research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a egfr clinical trial?
Eligibility criteria for egfr trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
EpiBiologics 1 trial
Peng Zhang 1 trial
Betta Pharmaceuticals Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT07462377 Phase 1
Recruiting
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Enrollment
110 pts
Location
United States, South...
Sponsor
EpiBiologics
View Trial →
NCT07742332 Phase 2
Recruiting
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
Enrollment
160 pts
Location
China
Sponsor
Peng Zhang
View Trial →
NCT07181499 Phase 2
Recruiting
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Enrollment
28 pts
Location
China
Sponsor
Betta Pharmaceuticals Co., Ltd...
View Trial →

Related Conditions

nsclc non small cell lung cancer (2) epidermal growth factor (1) epidermal growth factor receptor (1) epidermal growth factor receptor gene mutation (1) non small cell (1) non small cell lung (1) non small cell lung cancer (1) head and neck (1) head and neck cancer (1) head and neck cancers (1) head and neck squamous cell cancer (1) head and neck squamous cell carcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology